Generic Name and Formulations:
Methylphenidate HCl 20mg; ext-rel tabs; dye-free; contains sucrose.
Adults and Children:
Swallow whole. <6yrs: not established. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
Indications for METADATE ER:
Adults and Children:
Swallow whole. <6yrs: not recommended. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Glaucoma. Surgery. History of tics or Tourette's syndrome in patient or family.
History of drug dependence or alcoholism; monitor. Structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems: not recommended. Pre-existing hypertension. Assess cardiovascular status. Psychosis. Bipolar disorder. Mania. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Risk of peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth, HR, BP, CBC, differential, and platelet counts. Interrupt therapy if growth suppression occurs. Reduce dose or discontinue if paradoxical worsening of symptoms occur. Re-evaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH.
Headache, anorexia, abdominal pain, dizziness, rash, insomnia, nervousness, blood dyscrasias, weight loss, nausea, dyskinesias, tachycardia, arrhythmias; priapism, Tourette's syndrome, toxic psychosis, seizures, hypertension, visual disturbances.
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain